nach oben

Current Diabetes Reports

Erschienen in:

01.06.2013 | Diabetes and Other Diseases—Emerging Associations (D Aron, Section Editor)

Diabetes and HIV: Current Understanding and Future Perspectives

verfasst von: Sanjay Kalra, Navneet Agrawal

Erschienen in: Current Diabetes Reports | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Diabetes mellitus is a chronic disease with a higher risk of associated infections. HIV infection severely affects diabetic patients and acts as a significant health concern. Highly active antiretroviral therapy (HAART) has changed HIV from an acute infection to a chronic infection with associated significant metabolic abnormalities such as insulin resistance, impaired glucose tolerance, metabolic syndrome, diabetes, dyslipidemia, obesity, and lipodystrophy. These metabolic disturbances add complexity to the standards of care in HIV infection and further increase the risk for cardiovascular disease and renal complications. The co-association of diabetes and HIV needs to be managed appropriately to prevent mortality and morbidity and improve patient outcome. The current understanding of diabetes and other metabolic abnormalities along with management strategies in HIV infected patients are summarized in this article. The review also focuses on recent challenges in the diagnosis and management of co-existent diabetes and HIV infection.

•Global Report. UNAIDS Report on the Global AIDS Epidemic. 2010. Available at: http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf. The report gives the latest statistics for HIV worldwide.

Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–9.PubMedCrossRef

Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, et al. HIV infection and the risk of diabetes mellitus. AIDS. 2009;23:1227–34.PubMedCrossRef

••Calza L, Masetti G, Piergentili B, Trapani F, Cascavilla A, Manfredi R, et al. Prevalence of diabetes mellitus, hyperinsulinaemia, and metabolic syndrome among 755 adult patients with HIV-1 infection. Int J STD AIDS. 2011;22:43–5. A longer exposure to antiretroviral therapy and a diagnosis of lipodystrophy syndrome were significantly associated with both metabolic disturbances.PubMedCrossRef

••Galli L, Salpietro S, Pellicciotta G, Galliani A, Piatti P, Hasson H, et al. Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. Eur J Epidemiol. 2012;27(8):657–65. A recent study about prevalence of type 2 diabetes mellitus in HIV-infected subjects in healthy subjects.

Hadigan C. Diabetes, insulin resistance, and HIV. Curr Infect Dis Rep. 2006;8:69–75.PubMedCrossRef

Florescu D, Kotler DP. Insulin resistance, glucose intolerance, and diabetes mellitus in HIV-infected patients. Antivir Ther. 2007;12:149–62.PubMed

•Samaras K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr HIV/AIDS Rep. 2012;9:206–17. A recent review about current evidence base and clinical guidelines for diabetes and lipid management and cardiometabolic prevention in HIV-infected HAART recipients.PubMedCrossRef

Salehian B, Bilas J, Bazargan M, Abbasian M. Prevalence and incidence of diabetes in HIV-infected minority patients on protease inhibitors. J Natl Med Assoc. 2005;97:1088–92.PubMed

10.

Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res. 2006;4:79–85.PubMedCrossRef

11.

Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423–30.PubMedCrossRef

12.

•Das S. Insulin resistance and diabetes in HIV infection. Recent Pat Antiinfect Drug Discov. 2011;6:260–8. The present review article has the information of patients regarding the insulin resistance in HIV infection.PubMedCrossRef

13.

•Krishnan S, Shouten JT, Atkinson B, Brown T, Wohl T, McComsey GA, et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr. 2012;61(3):381–9. A recent study about the development of metabolic syndrome in HIV-infected individuals on ART, with virologic suppression and maintenance of high CD4+ T-cell counts as potentially modifiable factors that can reduce the risk of metabolic syndrome.

14.

Abdel-Khalek I, Moallem HJ, Fikrig S, Castells S. New onset diabetes mellitus in an HIV-positive adolescent. AIDS Patient Care STDS. 1998;12:167–9.PubMedCrossRef

15.

•Kalra S KB, Agrawal N, Unnikrishnan A. Understanding diabetes in patients with HIV/AIDS. Diabetol Metab Syndr. 2011;3(1):2. A review article on pathology of diabetes in HIV along with diagnosis and management.

16.

Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298–302.PubMedCrossRef

17.

Brar I, Shuter J, Thomas A, Daniels E, Absalon J. A comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviral-naive individuals vs individuals in the national health and nutritional examination survey cohort. J Acquir Immune Defic Syndr. 2007;45:66–71.PubMedCrossRef

18.

Kourtis AP, Bansil P, Kahn HS, Posner SF, Jamieson DJ. Diabetes trends in hospitalized HIV-infected persons in the United States, 1994-2004. Curr HIV Res. 2009;7:481–6.PubMedCrossRef

19.

Brambilla AM, Novati R, Calori G, Meneghini E, Vacchini D, Luzi L, et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS. 2003;17:1993–5.PubMedCrossRef

20.

Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010;33:2244–9.PubMedCrossRef

21.

Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology. 2004;40:115–9.PubMedCrossRef

22.

Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV cohort study. Clin Infect Dis. 2007;45:111–9.PubMedCrossRef

23.

Howard AA, Hoover DR, Anastos K, Wu X, Shi Q, Strickler HD, et al. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's interagency HIV study. J Acquir Immune Defic Syndr. 2010;54:152–9.PubMed

24.

Monroe A. HIV/AIDS and diabetes: minimizing risk, optimizing care. BETA. 2009;21:38–44.PubMed

25.

Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS. 2012;26:303–14.PubMedCrossRef

26.

Gonzalez-Tome MI, Ramos Amador JT, Guillen S, Solis I, Fernandez-Ibieta M, Munoz E, et al. Gestational diabetes mellitus in a cohort of HIV-1 infected women. HIV Med. 2008;9:868–74.PubMedCrossRef

27.

Gianotti N, Visco F, Galli L, Barda B, Piatti P, Salpietro S, et al. Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients. HIV Med. 2011;12:109–17.PubMedCrossRef

28.

De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2008;31:1224–9.PubMedCrossRef

29.

Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's interagency HIV study. AIDS. 2007;21:1739–45.PubMedCrossRef

30.

Srivanich N, Ngarmukos C, Sungkanuparph S. Prevalence of, and risk factors for pre-diabetes in HIV-1-infected patients in Bangkok, Thailand. J Int Assoc Physicians AIDS Care. 2010;9:358–61.CrossRef

31.

Revuelta MP. Cumulative insults to mitochondrial function may promote the emergence of 'syndrome X' and diabetes mellitus in HIV/HCV co-infected patients. Mitochondrion. 2004;4:175–84.PubMedCrossRef

32.

Jain MK, Aragaki C, Fischbach L, Gibson S, Arora R, May L, et al. Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. HIV Med. 2007;8:491–7.PubMedCrossRef

33.

Lo YC, Chang SY, Sheng WH, Hung CC, Chang SC. Association of pancreatic autoantibodies and human leukocyte antigen haplotypes with resolution of diabetes mellitus after therapy for hepatitis C virus infection in patients with HIV infection: case report and review of literature. Eur J Gastroenterol Hepatol. 2009;21:478–81.PubMedCrossRef

34.

Hamill M, Brook G. An association between HIV/HCV co-infection and diabetes mellitus–is there a need for routine blood glucose monitoring? J Clin Virol. 2005;33:176–8.PubMedCrossRef

35.

Rotger M, Gsponer T, Martinez R, Taffe P, Elzi L, Vernazza P, et al. Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. Clin Infect Dis. 2010;51:1090–8.PubMedCrossRef

36.

Holly JM, Amiel SA, Sandhu RR, Rees LH, Wass JA. The role of growth hormone in diabetes mellitus. J Endocrinol. 1988;118:353–64.PubMedCrossRef

37.

Smith JC, Evans LM, Wilkinson I, Goodfellow J, Cockcroft JR, Scanlon MF, et al. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin Endocrinol. 2002;56:493–501.CrossRef

38.

Schauster AC, Geletko SM, Mikolich DJ. Diabetes mellitus associated with recombinant human growth hormone for HIV wasting syndrome. Pharmacotherapy. 2000;20:1129–34.PubMedCrossRef

39.

Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr. 1999;21:209–16.PubMedCrossRef

40.

Trabattoni D, Schenal M, Cesari M, Castelletti E, Pacei M, Goldberg B, et al. Low interleukin-10 production is associated with diabetes in HIV-infected patients undergoing antiviral therapy. Med Microbiol Immunol. 2006;195:125–32.PubMedCrossRef

41.

Takarabe D, Rokukawa Y, Takahashi Y, Goto A, Takaichi M, Okamoto M, et al. Autoimmune diabetes in HIV-infected patients on highly active antiretroviral therapy. J Clin Endocrinol Metab. 2010;95:4056–60.PubMedCrossRef

42.

Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, et al. Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet. 2010;86:88–92.PubMedCrossRef

43.

••Kalra SUA, Raza SA, Bantwal G, Baruah MP, Latt TS, Shrestha D, et al. South Asian consensus guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. Indian J Endocr Metab. 2011;15:242–50. The recent South Asian Guidelines about diagnosis and management of diabetes in HIV patients.CrossRef

44.

Hresko RC, Hruz PW. HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4. PLoS One. 2011;6:e25237.PubMedCrossRef

45.

Deloumeaux J, Maachi M, Sow-Goerger MT, Lamaury I, Velayoudom FL, Cheret A, et al. Adiponectin and leptin in afro-Caribbean men and women with HIV infection: association with insulin resistance and type 2 diabetes. Diabetes Metab. 2011;37:98–104.PubMedCrossRef

46.

Idiculla J, Ravindra'n GD, D'Souza J, Singh G, Furruqh S. Diabetes mellitus, insulin resistance, and metabolic syndrome in HIV-positive patients in south India. Int J Gen Med. 2011;4:73–8.PubMedCrossRef

47.

Garg H, Joshi A, Mukherjee D. Cardiovascular complications of HIV infection and treatment. Cardiovasc Hematol Agents Med Chem. 2012 Aug 30 Accessed 15 Sept 2012

48.

Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (D:A:D study). Circulation. 2009;119:805–11.PubMedCrossRef

49.

Calza L. Renal toxicity associated with antiretroviral therapy. HIV Clin Trials. 2012;13:189–211.PubMedCrossRef

50.

Cohen DB, Allain TJ, Glover S, Chimbayo D, Dzamalala H, Hofland HW, et al. A survey of the management, control, and complications of diabetes mellitus in patients attending a diabetes clinic in Blantyre, Malawi, an area of high HIV prevalence. AmJTrop Med Hyg. 2010;83:575–81.CrossRef

51.

Medapalli RK, Parikh CR, Gordon K, Brown ST, Butt AA, Gibert CL, et al. Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the veterans aging cohort study. J Acquir Immune Defic Syndr. 2012;60:393–9.PubMedCrossRef

52.

Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. Racial differences in end-stage renal disease rates in HIV infection vs diabetes. J Am Soc Nephrol. 2007;18:2968–74.PubMedCrossRef

53.

Kim PS, Woods C, Dutcher L, Georgoff P, Rosenberg A, Mican JA, et al. Increased prevalence of albuminuria in HIV-infected adults with diabetes. PLoS One. 2011;6:e24610.PubMedCrossRef

54.

Kim PS, Woods C, Georgoff P, Crum D, Rosenberg A, Smith M, et al. A1C underestimates glycemia in HIV infection. Diabetes Care. 2009;32:1591–3.PubMedCrossRef

55.

Eckhardt BJ, Holzman RS, Kwan CK, Baghdadi J, Aberg JA. Glycated hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals. AIDS Patient Care STDS. 2012;26:197–201.PubMed

56.

Tien PC, Schneider MF, Cox C, Karim R, Cohen M, Sharma A, et al. Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr. 2012;61(3):334–40.

57.

Beatty GKM, Abbasi F, Chu J, Reaven GM, Rosen A, et al. Quantification of insulin-mediated glucose-disposal in HIV-infected individual: comparision of patients treated and untreated with protease inhibitors. J Acquir Immune Defic Syndr. 2003;33:34–40.PubMedCrossRef

58.

Fairchild AL, Alkon A. Back to the future? diabetes, HIV, and the boundaries of public health. J Health Polit Policy Law. 2007;32:561–93.PubMedCrossRef

59.

• American Diabetes Association (ADA) Clinical Practice Recommendations. American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35:S11–63. Recent ADA guidelines about medical care in diabetes with focus on patient centric approach.CrossRef

60.

Polo R, Jose Galindo M, Martinez E, Alvarez J, Arevalo JM, Asensi V. et al [recommendations of the study group for metabolic alterations/secretariat for the national AIDS plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection]. Enferm Infecc Microbiol Clin. 2006;24:96–117.PubMedCrossRef

61.

Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000;284:472–7.PubMedCrossRef

62.

Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab. 2002;87:4611–5.PubMedCrossRef

63.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.PubMedCrossRef

64.

Aberg JAKJ, Libman H, Emmanuel P, Anderson JR, Stone VE, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651–81.PubMedCrossRef

65.

Kalra S, Unnikrishnan AG, Raza SA, Bantwal G, Baruah MP, Latt TS, et al. South Asian consensus guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. Indian J Endocrinol Metab. 2011;15:242–50.PubMedCrossRef

66.

Kalra SKB, Nanda G. OPD management of ketosis in pregnancy: aspart vs regular insulin. Diabet Med. 2006;23:504.

67.

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.

68.

Grinspoon S. Diabetes mellitus, cardiovascular risk, and HIV disease. Circulation. 2009;119:770–2.PubMedCrossRef

69.

Dube MPSD, Henry WK, Aberg JA, Torriani FJ, Hodis HN, Schouten J, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the adult AIDS clinical trial group cardiovascular disease focus group. Clin Infect Dis. 2000;31:1216–24.PubMedCrossRef

70.

Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, et al. A randomized, open-label comparison of 3 highly active antiretroviral therapy regimens including 2 nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS. 2000;14:1171–80.PubMedCrossRef

71.

Janssens B, Van Damme W, Raleigh B, Gupta J, Khem S, Soy Ty K, et al. Offering integrated care for HIV/AIDS, diabetes and hypertension within chronic disease clinics in Cambodia. Bull World Health Organ. 2007;85:880–5.PubMed

72.

Tzoupis H, Leonis G, Megariotis G, Supuran CT, Mavromoustakos T, Papadopoulos MG. Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations. J Med Chem. 2012;55:5784–96.PubMedCrossRef

73.

Questions and answers on the review aliskiren-containing medicines: European Medicines Agency. 2012.

74.

Pandey K, Sinha PK, Rabidas V, Kumar N, Bimal S, Verma N, et al. HIV, visceral leishmaniasis, and Parkinsonism combined with diabetes mellitus and hyperuricaemia: a case report. Cases J. 2008;1:183.PubMedCrossRef

Titel: Diabetes and HIV: Current Understanding and Future Perspectives
verfasst von: Sanjay Kalra
Navneet Agrawal
Publikationsdatum: 01.06.2013
Verlag: Current Science Inc.
Erschienen in: Current Diabetes Reports / Ausgabe 3/2013
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-013-0369-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Diabetes and HIV: Current Understanding and Future Perspectives

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?

Diabetes Mellitus and Inflammation

Is the Risk and Nature of CVD the Same in Type 1 and Type 2 Diabetes?

The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists

Exercise and Diabetes-Related Cardiovascular Disease: Systematic Review of Published Evidence from Observational Studies and Clinical Trials

Risk vs Benefit in Diabetes Pharmacotherapy: a Rational Approach to Choosing Pharmacotherapy in Type 2 Diabetes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin